March 16, 2022 View Now | AI-powered Real-world Simulations for Faster and Value-based Rare Disease Drug Development On March 16 Quinten Health CEO Billy Amzal, PhD, MBA, presented AI-powered Real-world Simulations for Faster and Value-base
March 7, 2022 eTRANSAFE: Building a sustainable framework to share reproducible drug safety knowledge with the public domain
C-Path Welcomes ActiGraph C-Path is proud to welcome ActiGraph as the newest member of its Electronic Clinical Outcome Assessment (eCOA) Consortium. Compr
March 2, 2022 Measurement Comparability of Electronic and Paper Administration of Visual Analogue Scales: A Review of Published Studies
eCOA Consortium Announces Publication of Open Access Article C-Path’s eCOA Consortium is pleased to announce that “Measurement Comparability of Electronic and Paper Administration of Vi
February 23, 2022 Recommendations to Optimize the Use of Volumetric MRI in Huntington’s Disease in Clinical Trials C-Path’s Huntington’s Disease Regulatory Science Consortium (HD-RSC) has published a new paper on volumetric MRI-based....
C-Path and the European Joint Programme on Rare Diseases to Expand Global Impact and Partnership PARIS, France and TUCSON, Ariz., U.S., February 1, 2022 — Critical Path Institute (C-Path), an independent global nonprofit orga
January 31, 2022 The fragmented COVID-19 therapeutics research landscape: a living systematic review of clinical trial registrations evaluating priority pharmacological interventions
January 19, 2022 Rare Diseases Cures Accelerator Data and Analytics Platform (RDCA-DAP) best practices and recommendations for FAIR data, toward alignment with International Regulatory agencies
C-Path Appoints Health Outcomes Expert as Executive Director of the Rare Disease COA Consortium Dr. Lindsey Murray will lead C-Path’s New Rare Disease COA Consortium TUCSON, Ariz., January 13, 2022 — Critical Path Institut